{"disease":{"id":"chronic","name":"chronic"},"drugs":{"marketed":[{"drug_id":"dupilumab","indication_name":"Chronic sinusitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dupixent","generic_name":"DUPILUMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor subunit alpha","drug_class":"Interleukin-4 Receptor alpha Antagonist [EPC]","quality_score":62,"revenue":"14600","mechanism":"Dupixent blocks the interleukin-4 receptor, a key player in the immune system's inflammatory response."},{"drug_id":"vedolizumab","indication_name":"Chronic antibioticrefractory ileal pouchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Entyvio","generic_name":"vedolizumab","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Integrin alpha-4/beta-7","drug_class":"Integrin Receptor Antagonist [EPC]","quality_score":10,"revenue":"7300","mechanism":"Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue."},{"drug_id":"empagliflozin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jardiance","generic_name":"empagliflozin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":66,"revenue":"6500","mechanism":"SYNJARDY combines empagliflozin, which inhibits SGLT2 to increase urinary glucose excretion, and metformin HCl, which improves glucose tolerance and insulin sensitivity."},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or functional or anatomical asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"dapagliflozin","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"dapagliflozin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"onabotulinumtoxina","indication_name":"Chronic Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Botox","generic_name":"ONABOTULINUMTOXINA","company_name":"Allergan","drug_phase":"marketed","molecular_target":"SNAP-25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":60,"revenue":"5300","mechanism":"BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25."},{"drug_id":"rituxan","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"omalizumab","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xolair","generic_name":"omalizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"Anti-IgE [EPC]","quality_score":52,"revenue":"3200","mechanism":null},{"drug_id":"ibrutinib","indication_name":"Chronic graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imbruvica","generic_name":"ibrutinib","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Blk","drug_class":"Kinase Inhibitor [EPC]","quality_score":74,"revenue":"3200","mechanism":"Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells."},{"drug_id":"ibrutinib","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imbruvica","generic_name":"ibrutinib","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Blk","drug_class":"Kinase Inhibitor [EPC]","quality_score":74,"revenue":"3200","mechanism":"Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells."},{"drug_id":"humax-cd20","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arzerra","generic_name":"HuMax-CD20","company_name":"Glaxo Grp Ltd","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":null,"revenue":"3198","mechanism":"Arzerra works by binding to the CD20 protein on B cells, marking them for destruction by the immune system."},{"drug_id":"umeclidinium","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Incruse Ellipta","generic_name":"UMECLIDINIUM","company_name":"Glaxo Grp England","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Anticholinergic","quality_score":70,"revenue":"3100","mechanism":"Umeclidinium works by blocking the M4 muscarinic acetylcholine receptor to relax airway smooth muscle and improve breathing."},{"drug_id":"umeclidinium","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Incruse Ellipta","generic_name":"UMECLIDINIUM","company_name":"Glaxo Grp England","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Anticholinergic","quality_score":70,"revenue":"3100","mechanism":"Umeclidinium works by blocking the M4 muscarinic acetylcholine receptor to relax airway smooth muscle and improve breathing."},{"drug_id":"acalabrutinib","indication_name":"Chronic lymphocyticleukemia/small lymphocytic lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calquence","generic_name":"ACALABRUTINIB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase BTK","drug_class":"Kinase Inhibitor [EPC]","quality_score":59,"revenue":"3100","mechanism":"Calquence works by blocking the activity of the BTK enzyme, which is essential for the activation and survival of B cells."},{"drug_id":"fluticasone-furoate","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arnuity Ellipta","generic_name":"FLUTICASONE FUROATE","company_name":"Haleon Us Holdings","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":62,"revenue":"3100","mechanism":""},{"drug_id":"fluticasone-furoate","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arnuity Ellipta","generic_name":"FLUTICASONE FUROATE","company_name":"Haleon Us Holdings","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":62,"revenue":"3100","mechanism":""},{"drug_id":"fluticasone-furoate","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arnuity Ellipta","generic_name":"FLUTICASONE FUROATE","company_name":"Haleon Us Holdings","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":62,"revenue":"3100","mechanism":""},{"drug_id":"vilanterol","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Breo Ellipta","generic_name":"VILANTEROL","company_name":"Glaxo Grp Ltd","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":60,"revenue":"3100","mechanism":"Breo Ellipta works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"vilanterol","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Breo Ellipta","generic_name":"VILANTEROL","company_name":"Glaxo Grp Ltd","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":60,"revenue":"3100","mechanism":"Breo Ellipta works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"desonide","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"budesonide","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"desonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"budesonide","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"bgb-3111","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brukinsa","generic_name":"BGB-3111","company_name":"Beigene Usa Inc","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase BTK","drug_class":"Kinase Inhibitor [EPC]","quality_score":72,"revenue":"2700","mechanism":"Brukinsa blocks the BTK protein, which is involved in the activation of B cells."},{"drug_id":"ruxolitinib","indication_name":"Chronic graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jakafi","generic_name":"RUXOLITINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","drug_class":"","quality_score":null,"revenue":"2600","mechanism":null},{"drug_id":"venetoclax","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venclexta","generic_name":"venetoclax","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"BCL-2 Inhibitor [EPC]","quality_score":80,"revenue":"2583","mechanism":"Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein."},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"tiotropium-bromide","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spiriva","generic_name":"TIOTROPIUM BROMIDE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic","quality_score":10,"revenue":"2500","mechanism":"Spiriva works by blocking the action of a chemical called acetylcholine, which causes airway muscles to contract and narrow the airways."},{"drug_id":"tiotropium-bromide","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spiriva","generic_name":"TIOTROPIUM BROMIDE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic","quality_score":10,"revenue":"2500","mechanism":"Spiriva works by blocking the action of a chemical called acetylcholine, which causes airway muscles to contract and narrow the airways."},{"drug_id":"romiplostim","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nplate","generic_name":"ROMIPLOSTIM","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist [EPC]","quality_score":70,"revenue":"1524.0","mechanism":"Nplate works by binding to the thrombopoietin receptor to stimulate platelet production."},{"drug_id":"nivestym","indication_name":"Chronic idiopathic neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"canakinumab","indication_name":"Systemic onset juvenile chronic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ilaris","generic_name":"CANAKINUMAB","company_name":"Novartis Pharms","drug_phase":"marketed","molecular_target":"Interleukin-1 beta","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":59,"revenue":"1369","mechanism":""},{"drug_id":"dabigatran","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran etexilate","company_name":"Generic (originally Boehringer Ingelheim)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","quality_score":69,"revenue":"1200","mechanism":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring."},{"drug_id":"obinutuzumab","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gazyva","generic_name":"obinutuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":"1200","mechanism":"Gazyva binds to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"cyclophosphamide","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"cyclophosphamide","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"asciminib","indication_name":"Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"","quality_score":69,"revenue":"894","mechanism":"Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells."},{"drug_id":"buprenorphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"canagliflozin","indication_name":"Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invokana","generic_name":"CANAGLIFLOZIN","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":71,"revenue":"800","mechanism":"Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption."},{"drug_id":"buprenorphine-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"Buprenorphine Hydrochloride","company_name":"Indivior","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"partial opioid agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine is a partial agonist at mu-opioid receptors and antagonist at kappa-opioid receptors."},{"drug_id":"buprenorphine","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Subutex","generic_name":"BUPRENORPHINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"mu-opioid receptor, kappa-opioid receptor","drug_class":"Partial Opioid Agonist","quality_score":75,"revenue":"800","mechanism":"Buprenorphine binds to mu-opioid receptors as a partial agonist and kappa-opioid receptors as an antagonist."},{"drug_id":"bosulif","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"Bosutinib Monohydrate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif blocks the abnormal tyrosine kinase activity in cancer cells, inhibiting their growth and proliferation."},{"drug_id":"bosutinib","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"bosutinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells."},{"drug_id":"bosutinib","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"bosutinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells."},{"drug_id":"bosutinib","indication_name":"Chronic Phase Ph+ CML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"bosutinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells."},{"drug_id":"bosulif","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"Bosutinib Monohydrate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif blocks the abnormal tyrosine kinase activity in cancer cells, inhibiting their growth and proliferation."},{"drug_id":"roxadustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evrenzo","generic_name":"ROXADUSTAT","company_name":"Astellas Pharma Europe B.V.","drug_phase":"marketed","molecular_target":"Thyroid hormone receptor beta","drug_class":"","quality_score":35,"revenue":"600","mechanism":""},{"drug_id":"finerenone","indication_name":"Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kerendia","generic_name":"FINERENONE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]","quality_score":59,"revenue":"600","mechanism":"Kerendia works by blocking the mineralocorticoid receptor, a protein that regulates sodium and potassium levels in the body."},{"drug_id":"eltrombopag","indication_name":"Persistent or Chronic ITP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"eltrombopag","indication_name":"Thrombocytopenia in Chronic Hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"eltrombopag","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"dasatinib","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"dasatinib","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"dasatinib","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"dasatinib","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"valsartan","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diovan","generic_name":"VALSARTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":"447","mechanism":"Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"valsartan","indication_name":"Chronic heart failure in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diovan","generic_name":"VALSARTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":"447","mechanism":"Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"retacrit","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"Epoetin Alfa-Epbx","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":"400","mechanism":"Epoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"epoetin-alfa","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"EPOETIN ALFA","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating Agent","quality_score":63,"revenue":"400","mechanism":"Epogen works by binding to the erythropoietin receptor, triggering a cascade of signals that stimulate the production of red blood cells."},{"drug_id":"nilotinib","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tasigna","generic_name":"NILOTINIB","company_name":"Cipla","drug_phase":"marketed","molecular_target":"Bcr/Abl fusion protein","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"400","mechanism":"Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML."},{"drug_id":"nilotinib","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tasigna","generic_name":"NILOTINIB","company_name":"Cipla","drug_phase":"marketed","molecular_target":"Bcr/Abl fusion protein","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"400","mechanism":"Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML."},{"drug_id":"nilotinib","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tasigna","generic_name":"NILOTINIB","company_name":"Cipla","drug_phase":"marketed","molecular_target":"Bcr/Abl fusion protein","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"400","mechanism":"Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML."},{"drug_id":"azithromycin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zithromax","generic_name":"azithromycin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor","drug_class":"Macrolide antibiotic (azalide)","quality_score":67,"revenue":"399","mechanism":"Macrolide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with an exceptionally long tissue half-life."},{"drug_id":"fluticasone-propionate","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic chronic lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","indication_name":"Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Respiratory Syncytial Virus Prefusion F Subunit Vaccine","generic_name":"respiratory-syncytial-virus-prefusion-f-subunit-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Respiratory Syncytial Virus (RSV)","drug_class":"Vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"enarodustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enaroy","generic_name":"ENARODUSTAT","company_name":"Japan Tabacco","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"danuglipron","indication_name":"Treatment of acute and chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Danuglipron","generic_name":"danuglipron","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 receptor agonist","quality_score":49,"revenue":null,"mechanism":"Danuglipron is a small-molecule GLP-1 receptor agonist."},{"drug_id":"dapaglifozin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"dapaglifozin","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"daprodustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jesduvroq","generic_name":"DAPRODUSTAT","company_name":"GSK","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Jesduvroq works by activating hypoxia-inducible factor prolyl hydroxylase inhibitors, which increases the production of erythropoietin, a hormone that stimulates red blood cell production."},{"drug_id":"interferon-alfa-2b","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"interferon-alfa-2b","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"rilzabrutinib","indication_name":"persistent or chronic immune thrombocytopenia (ITP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wayrilz","generic_name":"RILZABRUTINIB","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Wayrilz works by blocking a specific enzyme that helps platelet-destroying immune cells function."},{"drug_id":"chlorothiazide","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chlorothiazide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chlorothiazide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"vericiguat","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verquvo","generic_name":"VERICIGUAT","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1","drug_class":"Soluble Guanylate Cyclase Stimulator [EPC]","quality_score":10,"revenue":null,"mechanism":"Verquvo works by stimulating the enzyme guanylate cyclase to increase levels of a molecule called cGMP, which helps to relax blood vessels and improve heart function."},{"drug_id":"axatilimab","indication_name":"chronic graft-versus-host disease (cGVHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niktimvo","generic_name":"AXATILIMAB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Colony Stimulating Factor-1 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Niktimvo blocks the Colony Stimulating Factor-1 Receptor to reduce inflammation and prevent damage to healthy tissues."},{"drug_id":"exjade","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Exjade","company_name":"DisperSol Technologies, LLC","drug_phase":"marketed","molecular_target":"Flavin reductase (NADPH), Lysine-specific demethylase 5A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"elobixibat","indication_name":"Chronic constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Goofice","generic_name":"ELOBIXIBAT","company_name":"EA Pharma","drug_phase":"discontinued","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Goofice works by inhibiting the ileal sodium/bile acid cotransporter to stimulate bowel movements."},{"drug_id":"glucocerebrosidase","indication_name":"Chronic non-neuropathic Gaucher's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"glucocerebrosidase","company_name":"National Center for Research Resources (NCRR)","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"beclabuvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BECLABUVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"fludroxycortide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordran","generic_name":"fludroxycortide","company_name":"Aqua Pharms","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"amoxycillin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"amoxycillin","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"amoxycillin","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"neupogen","indication_name":"Chronic idiopathic neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"daunorubicin","indication_name":"Blast crisis of chronic myeloidleukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"olodaterol","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Striverdi Respimat","generic_name":"OLODATEROL","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":55,"revenue":null,"mechanism":"Striverdi Respimat works by stimulating the beta-2 receptors in the lungs to relax airway muscles and improve breathing."},{"drug_id":"roflumilast","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daliresp","generic_name":"ROFLUMILAST","company_name":"Arcutis","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"Phosphodiesterase 4 Inhibitor [EPC]","quality_score":63,"revenue":null,"mechanism":"Daliresp works by blocking an enzyme called phosphodiesterase 4, which helps reduce inflammation in the body."},{"drug_id":"roflumilast","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daliresp","generic_name":"ROFLUMILAST","company_name":"Arcutis","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"Phosphodiesterase 4 Inhibitor [EPC]","quality_score":63,"revenue":null,"mechanism":"Daliresp works by blocking an enzyme called phosphodiesterase 4, which helps reduce inflammation in the body."},{"drug_id":"revefenacin","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yupelri","generic_name":"REVEFENACIN","company_name":"Mylan Ireland Ltd","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic [EPC]","quality_score":10,"revenue":null,"mechanism":"Yupelri works by blocking the action of a chemical called acetylcholine, which stimulates the muscles in the airways, leading to bronchodilation."},{"drug_id":"inqovi","indication_name":"Chronic myelomonocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inqovi","generic_name":"Inqovi","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"Cytidine deaminase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Inqovi works by blocking the enzyme cytidine deaminase, allowing chemotherapy medications to be more effective."},{"drug_id":"azacitidine","indication_name":"Chronic myelomonocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"tramadol","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultram","generic_name":"tramadol","company_name":"Janssen","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"mechlorethamine","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valchlor","generic_name":"MECHLORETHAMINE","company_name":"Recordati","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"mechlorethamine","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valchlor","generic_name":"MECHLORETHAMINE","company_name":"Recordati","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"deferoxamine","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Desferal","generic_name":"DEFEROXAMINE","company_name":"Mitem Pharma","drug_phase":"marketed","molecular_target":"Deoxyhypusine hydroxylase","drug_class":"Iron Chelator","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime","indication_name":"Acute bacterial exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"lamivudine","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epivir","generic_name":"LAMIVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Deoxycytidine kinase","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":66,"revenue":null,"mechanism":"Epivir works by mimicking the building blocks of DNA to prevent the replication of viral genetic material."},{"drug_id":"hydromorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"HYDROMORPHONE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"mu-opioid receptor","drug_class":"Opioid Agonist","quality_score":66,"revenue":null,"mechanism":"Hydromorphone binds primarily to mu-opioid receptors, producing analgesia without a ceiling effect."},{"drug_id":"desoximetasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topicort","generic_name":"DESOXIMETASONE","company_name":"Taro","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fludarabine","indication_name":"B-cell chronic lymphocytic leukemia (CLL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludarabine Phosphate","generic_name":"FLUDARABINE","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Fludarabine works by interfering with DNA synthesis, thereby inhibiting cancer cell growth and proliferation."},{"drug_id":"sulfamethoxazole","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantanol","generic_name":"SULFAMETHOXAZOLE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sulfamethoxazole","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantanol","generic_name":"SULFAMETHOXAZOLE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sulfamethoxazole","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantanol","generic_name":"SULFAMETHOXAZOLE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"levocetirizine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xyzal","generic_name":"LEVOCETIRIZINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"formoterol","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"formoterol","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"fluocinolone-acetonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Derma-Smoothe/Fs","generic_name":"FLUOCINOLONE ACETONIDE","company_name":"Eurofarma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"clocortolone-pivalate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cloderm","generic_name":"CLOCORTOLONE PIVALATE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"itopride","indication_name":"Chronic gastritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ganaton","generic_name":"ITOPRIDE","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"itopride","quality_score":47,"revenue":null,"mechanism":"Itopride works by increasing the release of a natural chemical called acetylcholine in the stomach, which helps to stimulate digestive processes."},{"drug_id":"duloxetine","indication_name":"Chronic Musculoskeletal Pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cymbalta","generic_name":"duloxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine reuptake","drug_class":"Serotonin and norepinephrine reuptake inhibitor (SNRI)","quality_score":68,"revenue":null,"mechanism":"Potentiates serotonergic and noradrenergic activity in the CNS through unknown exact mechanisms."},{"drug_id":"ampicillin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"moxifloxacin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"moxifloxacin","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"moxifloxacin","indication_name":"Haemophilus Parainfluenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"moxifloxacin","indication_name":"Klebsiella Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"moxifloxacin","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"moxifloxacin","indication_name":"Staphylococcus Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"moxifloxacin","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"fexofenadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allegra","generic_name":"fexofenadine","company_name":"Generic (originally Hoechst Marion Roussel/Sanofi)","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor","drug_class":"Second-generation antihistamine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"gemifloxacin-mesylate","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Factive","generic_name":"GEMIFLOXACIN MESYLATE","company_name":"Lg Chem Ltd","drug_phase":"marketed","molecular_target":"","drug_class":"Quinolone Antimicrobial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"carfenazine","indication_name":"Chronic schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carphenazin","generic_name":"carfenazine","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"gemifloxacin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Factive","generic_name":"GEMIFLOXACIN","company_name":"Lg Chem Ltd","drug_phase":"marketed","molecular_target":"","drug_class":"Quinolone Antimicrobial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"trimethoprim","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trimethoprim","generic_name":"TRIMETHOPRIM","company_name":"Dr Reddys Labs Sa","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trimethoprim","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trimethoprim","generic_name":"TRIMETHOPRIM","company_name":"Dr Reddys Labs Sa","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trimethoprim","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trimethoprim","generic_name":"TRIMETHOPRIM","company_name":"Dr Reddys Labs Sa","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cloxacillin","indication_name":"Continuation Therapy for Chronic Osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methocillin S","generic_name":"CLOXACILLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"cloxacillin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ergocalciferol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Chronic ulcerative proctitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cefaclor","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceclor","generic_name":"CEFACLOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"cefaclor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"cefaclor","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceclor","generic_name":"CEFACLOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"cefaclor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"cefaclor","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceclor","generic_name":"CEFACLOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"cefaclor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"boceprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Victrelis","generic_name":"BOCEPREVIR","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Chymase","drug_class":"Hepatitis C Virus NS3/4A Protease Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"ulobetasol-propionate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultravate","generic_name":"ulobetasol propionate","company_name":"Ranbaxy","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ulobetasol propionate","quality_score":10,"revenue":null,"mechanism":"Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation."},{"drug_id":"grazoprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepatier","generic_name":"GRAZOPREVIR","company_name":"Merck & Co.","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Zepatier blocks the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating."},{"drug_id":"salbutamol","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proventil","generic_name":"salbutamol","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-dipropionate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diprolene","generic_name":"BETAMETHASONE DIPROPIONATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":"Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system."},{"drug_id":"amisulpride","indication_name":"Chronic schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Barhemsys","generic_name":"AMISULPRIDE","company_name":"Acacia","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Dopamine-2 Receptor Antagonist [EPC]","quality_score":57,"revenue":null,"mechanism":"Barhemsys works by blocking dopamine receptors in the brain."},{"drug_id":"cefuroxime-axetil","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime-axetil","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime-axetil","indication_name":"Haemophilus Parainfluenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime-axetil","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftin","generic_name":"CEFUROXIME AXETIL","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":50,"revenue":null,"mechanism":"Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"linaclotide","indication_name":"Chronic idiopathic constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Linzess","generic_name":"LINACLOTIDE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Heat-stable enterotoxin receptor","drug_class":"Guanylate Cyclase-C Agonist [EPC]","quality_score":57,"revenue":null,"mechanism":"Linzess works by activating the heat-stable enterotoxin receptor to increase fluid secretion in the intestines."},{"drug_id":"paricalcitol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zemplar","generic_name":"PARICALCITOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D2 Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Zemplar works by activating the Vitamin D3 receptor, mimicking the natural effects of Vitamin D to regulate calcium levels and bone health."},{"drug_id":"nandrolone-decanoate","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nandrolone Decanoate","generic_name":"NANDROLONE DECANOATE","company_name":"Woodward Specl","drug_phase":"marketed","molecular_target":"Sex hormone-binding globulin","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"captopril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Capozide 25/15","generic_name":"CAPTOPRIL","company_name":"Aarxion Anda Hlding","drug_phase":"marketed","molecular_target":"Renin","drug_class":"Thiazide Diuretic [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"rimabotulinumtoxinb","indication_name":"Chronic Sialorrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Myobloc","generic_name":"RIMABOTULINUMTOXINB","company_name":"Elan Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Myobloc works by blocking the release of acetylcholine, a chemical messenger that signals muscles to contract."},{"drug_id":"mesalazine","indication_name":"Chronic ulcerative proctitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rowasa","generic_name":"Mesalazine","company_name":"Meda Pharms","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Aminosalicylate [EPC]","quality_score":65,"revenue":null,"mechanism":"Rowasa works by blocking the production of prostaglandins, which are chemicals that cause inflammation in the rectum and colon."},{"drug_id":"mesalazine","indication_name":"Chronic ulcerative rectosigmoiditis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rowasa","generic_name":"Mesalazine","company_name":"Meda Pharms","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Aminosalicylate [EPC]","quality_score":65,"revenue":null,"mechanism":"Rowasa works by blocking the production of prostaglandins, which are chemicals that cause inflammation in the rectum and colon."},{"drug_id":"belumosudil","indication_name":"Chronic graft-versus-host disease (chronic GVHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezurock","generic_name":"BELUMOSUDIL","company_name":"Kadmon Pharms Llc","drug_phase":"marketed","molecular_target":"Rho-associated protein kinase 1","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Rezurock works by inhibiting the Rho-associated protein kinase 1 enzyme, which plays a key role in inflammation and immune response."},{"drug_id":"quinapril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Accupril","generic_name":"QUINAPRIL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"difelikefalin","indication_name":"Pruritus associated with chronic kidney disease (CKD-aP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Korsuva","generic_name":"DIFELIKEFALIN","company_name":"Vifor Intl","drug_phase":"marketed","molecular_target":"Kappa-type opioid receptor","drug_class":"Kappa Opioid Receptor Agonist","quality_score":48,"revenue":null,"mechanism":"Korsuva works by activating the kappa-type opioid receptor, which helps to reduce itching."},{"drug_id":"betamethasone-valerate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone Valerate","generic_name":"BETAMETHASONE VALERATE","company_name":"Fougera Pharms Inc","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cinacalcet","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sensipar","generic_name":"CINACALCET","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"Calcium-sensing Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood."},{"drug_id":"fludarabine-phosphate","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludara","generic_name":"FLUDARABINE PHOSPHATE","company_name":"Nihon Schering K.K.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fludara works by interfering with the production of DNA and RNA in cancer cells, ultimately leading to cell death."},{"drug_id":"glycopyrronium-bromide","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cuvposa","generic_name":"GLYCOPYRRONIUM BROMIDE","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":62,"revenue":null,"mechanism":"Cuvposa works by blocking the action of a chemical called acetylcholine, which stimulates the muscarinic receptors in the body."},{"drug_id":"epoetin-zeta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silapo","generic_name":"EPOETIN ZETA","company_name":"Hospira UK Limited","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"bendamustine","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treanda","generic_name":"BENDAMUSTINE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Alkylating Drug","quality_score":63,"revenue":null,"mechanism":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"arformoterol","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brovana","generic_name":"ARFORMOTEROL","company_name":"Lupin","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":58,"revenue":null,"mechanism":"Brovana works by activating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"arformoterol","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brovana","generic_name":"ARFORMOTEROL","company_name":"Lupin","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":58,"revenue":null,"mechanism":"Brovana works by activating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"gefapixant-citrate","indication_name":"Refractory chronic cough","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lyfnua","generic_name":"GEFAPIXANT CITRATE","company_name":"Msd K.K.","drug_phase":"marketed","molecular_target":"P2X purinoceptor 3","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"dabigatran-etexilate","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"sulfamethizole","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfurine","generic_name":"SULFAMETHIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"sulfamethizole","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sulfamethizole","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfurine","generic_name":"SULFAMETHIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"sulfamethizole","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"terfenadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seldane","generic_name":"TERFENADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"High Risk QT Prolonging Agents","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"albuterol","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ProAir","generic_name":"albuterol","company_name":"Generic (originally Allen & Hanburys/GSK)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"SABA (Short-acting beta-2 agonist)","quality_score":56,"revenue":null,"mechanism":"Short-acting beta-2 adrenergic agonist (SABA) that relaxes bronchial smooth muscle, providing rapid relief of bronchospasm."},{"drug_id":"astemizole","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hismanal","generic_name":"ASTEMIZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"omacetaxine-mepesuccinate","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synribo","generic_name":"OMACETAXINE MEPESUCCINATE","company_name":"Teva Pharms Intl","drug_phase":"marketed","molecular_target":"","drug_class":"omacetaxine mepesuccinate","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"methoxy-polyethylene-glycol-epoetin-beta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mircera","generic_name":"METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"erythropoietin receptor","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Mircera activates erythropoietin receptors, increasing red cell production in response to hypoxia."},{"drug_id":"adefovir-dipivoxil","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hepsera","generic_name":"ADEFOVIR DIPIVOXIL","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"DNA polymerase subunit gamma-1","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":64,"revenue":null,"mechanism":"Hepsera works by mimicking a building block of DNA, which it uses to trick the Hepatitis B Virus into incorporating faulty genetic material, ultimately halting its replication."},{"drug_id":"amoxicillin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"amoxicillin","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"amoxicillin","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"vindesin","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vindesin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"eplerenone","indication_name":"Chronic Heart Failure Following Myocardial Infarction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inspra","generic_name":"EPLERENONE","company_name":"Upjohn","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"Aldosterone Antagonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Inspra works by blocking the action of aldosterone, a hormone that can cause the body to retain too much salt and water."},{"drug_id":"indacaterol","indication_name":"Prevention of Bronchospasm with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arcapta Neohaler","generic_name":"INDACATEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Chronic Bacterial Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"candesartan-cilexetil","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atacand","generic_name":"CANDESARTAN CILEXETIL","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker","quality_score":10,"revenue":null,"mechanism":"Atacand blocks the action of angiotensin II, a hormone that constricts blood vessels, to lower blood pressure and improve heart function."},{"drug_id":"daklinza","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daklinza","company_name":"Genuine Research Center, Egypt","drug_phase":"phase_1","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Genome polyprotein, Nonstructural protein 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"daunorubicine","indication_name":"Blast crisis of chronic myeloidleukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ivabradine","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Corlanor","generic_name":"IVABRADINE","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1","drug_class":"Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"verapamil-hydrochloride","indication_name":"Chronic stable angina (classic effort-associated angina)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"verapamil-hydrochloride","indication_name":"Control of ventricular rate at rest in patients with chronic atrial flutter and/or atrial fibrillation (in association with digitalis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"verapamil-hydrochloride","indication_name":"Control of ventricular rate during stress in patients with chronic atrial flutter and/or atrial fibrillation (in association with digitalis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"epogen","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epogen","company_name":"Johns Hopkins University","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic kidney disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic liver disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic heart disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic lung disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Acute Bacterial Exacerbation of Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of chronic pain associated with adult patients with multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"alatrofloxacin","indication_name":"Chronic Bacterial Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALATROFLOXACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"alatrofloxacin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"colchicine","indication_name":"Chronic gouty arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Colcrys","generic_name":"COLCHICINE","company_name":"Scilex Pharms","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Alkaloid [EPC]","quality_score":10,"revenue":null,"mechanism":"Colcrys works by inhibiting the activity of a specific enzyme called serine/threonine-protein kinase pim-1."},{"drug_id":"linzess","indication_name":"Chronic idiopathic constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Linzess","company_name":"TriHealth Inc.","drug_phase":"discontinued","molecular_target":"Heat-stable enterotoxin receptor, Heat-stable enterotoxin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cefprozil","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefzil","generic_name":"cefprozil","company_name":"Teva Pharmaceuticals USA","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"cefprozil","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefzil","generic_name":"cefprozil","company_name":"Teva Pharmaceuticals USA","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"cefprozil","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefzil","generic_name":"cefprozil","company_name":"Teva Pharmaceuticals USA","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"cefprozil","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefzil","generic_name":"cefprozil","company_name":"Teva Pharmaceuticals USA","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"metoprolol","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopressor","generic_name":"metoprolol","company_name":"Generic (originally Ciba-Geigy/Novartis)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Beta-1 selective blocker","quality_score":58,"revenue":null,"mechanism":"Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand."},{"drug_id":"gleevec","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"gleevec","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"gleevec","indication_name":"Chronic eosinophilic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"gleevec","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"gleevec","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"frusemide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Frusemide","company_name":"Melbourne Health","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"frusemide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Frusemide","company_name":"Melbourne Health","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"homoharringtonine","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Homoharringtonine","company_name":"ChemGenex Pharmaceuticals","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"procrit","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Procrit","company_name":"University of Louisville","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"oxycodone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OxyContin","generic_name":"oxycodone","company_name":"Purdue Pharma","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"campath","indication_name":"Recurrent chronic lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Campath","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"campath","indication_name":"Refractory chronic lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Campath","company_name":"National Heart, Lung, and Blood Institute (NHLBI)","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"lisinopril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zestril","generic_name":"lisinopril","company_name":"Generic (originally Merck/AstraZeneca)","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme, Angiotensin-converting enzyme","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, lowering blood pressure and reducing cardiac workload."},{"drug_id":"naltrexon","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naltrexon","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"calciferol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"avelox","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avelox","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avelox","indication_name":"Haemophilus Parainfluenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avelox","indication_name":"Klebsiella Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avelox","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avelox","indication_name":"Staphylococcus Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avelox","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"torasemide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Torasemide","company_name":"Medical University of Warsaw","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"torasemide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Torasemide","company_name":"Medical University of Warsaw","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"azacytidine","indication_name":"Chronic myelomonocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"azacytidine","company_name":"Assistance Publique Hopitaux De Marseille","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"glycopyrrolate","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glycopyrrolate","company_name":"Yonsei University","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"kineret","indication_name":"Chronic infantile neurological, cutaneous and articular syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anakinra","generic_name":"Kineret","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist","quality_score":41,"revenue":null,"mechanism":""},{"drug_id":"ensifentrine","indication_name":"chronic obstructive pulmonary disease (COPD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ohtuvayre","generic_name":"ENSIFENTRINE","company_name":"Verona Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Phosphodiesterase 3 Inhibitor [EPC]","quality_score":47,"revenue":null,"mechanism":"Ohtuvayre works by blocking an enzyme called phosphodiesterase 3, which helps to increase the levels of a molecule called cyclic AMP in the lungs."},{"drug_id":"cetirizine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyrtec","generic_name":"cetirizine","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2","drug_class":"Second-generation antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"peginterferon","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Peginterferon","company_name":"Ziv Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"peginterferon","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Peginterferon","company_name":"Ziv Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"viread","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Viread","company_name":"Replicor Inc.","drug_phase":"marketed","molecular_target":"Gag-Pol polyprotein, Reverse transcriptase/RNaseH","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"nasonex","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"nasonex","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pegasys","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pegasys","company_name":"Zealand University Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"pegasys","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pegasys","company_name":"Zealand University Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"sobrerol","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"sobrerol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adempas","indication_name":"Chronic thromboembolic pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adempas","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1, cAMP-specific 3',5'-cyclic phosphodiesterase 7B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"mesa","indication_name":"Chronic ulcerative proctitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MESA","company_name":"Meda Pharms","drug_phase":"marketed","molecular_target":"Arachidonate 5-lipoxygenase, Peroxisome proliferator-activated receptor gamma, Prostaglandin G/H synthase 1","drug_class":"","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"mesa","indication_name":"Chronic ulcerative rectosigmoiditis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MESA","company_name":"Meda Pharms","drug_phase":"marketed","molecular_target":"Arachidonate 5-lipoxygenase, Peroxisome proliferator-activated receptor gamma, Prostaglandin G/H synthase 1","drug_class":"","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"almitrine","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duxil","generic_name":"ALMITRINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"almitrine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"clevudine","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levovir","generic_name":"CLEVUDINE","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"clevudine","quality_score":null,"revenue":null,"mechanism":"Levovir works by inhibiting viral DNA synthesis, specifically targeting the hepatitis B virus."},{"drug_id":"haloperidol","indication_name":"Chronic schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Haldol","generic_name":"haloperidol","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Typical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-benzoate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone 17-Benzoate","generic_name":"BETAMETHASONE BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methylclothiazide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enduron","generic_name":"methylclothiazide","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methylclothiazide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enduron","generic_name":"methylclothiazide","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"androstanolone","indication_name":"Anemia of chronic renal failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neodrol","generic_name":"androstanolone","company_name":"","drug_phase":"unknown","molecular_target":"Sex hormone-binding globulin","drug_class":"androstanolone","quality_score":null,"revenue":null,"mechanism":"Neodrol works by binding to androgen receptors, mimicking the effects of natural androgens like testosterone."},{"drug_id":"hydrocortisone","indication_name":"Chronic ulcerative proctitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prulifloxacin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PRULIFLOXACIN","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"prulifloxacin","quality_score":0,"revenue":null,"mechanism":"Prulifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting bacterial DNA replication."},{"drug_id":"vindesine","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eldisine","generic_name":"VINDESINE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"vindesine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"naftidrofuryl","indication_name":"Chronic Occlusive Peripheral Arterial Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nafronyl","generic_name":"naftidrofuryl","company_name":"","drug_phase":"unknown","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"naftidrofuryl","quality_score":null,"revenue":null,"mechanism":"Nafronyl works by interacting with the 5-hydroxytryptamine receptor 2A to improve blood flow and reduce vascular resistance."},{"drug_id":"adefovir","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ADEFOVIR","company_name":"","drug_phase":"discontinued","molecular_target":"DNA polymerase subunit gamma-1, Capsid protein, Protein P","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Adefovir is an antiviral medication used to treat chronic hepatitis B in adults and adolescents, with common side effects including fatigue, headache, and stomach pain."},{"drug_id":"chlortalidone","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Combipres","generic_name":"Chlortalidone","company_name":"University Hospital Birmingham","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 7","drug_class":"Thiazide-like Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chlortalidone","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Combipres","generic_name":"Chlortalidone","company_name":"University Hospital Birmingham","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 7","drug_class":"Thiazide-like Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"uracil-mustard","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uramustin","generic_name":"URACIL MUSTARD","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"uracil mustard","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"uracil-mustard","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uramustin","generic_name":"URACIL MUSTARD","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"uracil mustard","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"part-c-met097","indication_name":"Treatment of Chronic Myeloid Leukemia (CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of chronic lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aclidinium-bromide","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tudorza Pressair","generic_name":"ACLIDINIUM BROMIDE","company_name":"Covis","drug_phase":"marketed","molecular_target":"M3 receptors, beta 2 -adrenergic receptors","drug_class":"Anticholinergic","quality_score":10,"revenue":null,"mechanism":"DUAKLIR PRESSAIR combines aclidinium, an anticholinergic, and formoterol, a beta 2 -adrenergic agonist, to provide bronchodilation in COPD."},{"drug_id":"fentanyl","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duragesic","generic_name":"fentanyl","company_name":"Johnson & Johnson (Janssen Pharmaceutica)","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid analgesic","quality_score":55,"revenue":null,"mechanism":"Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia."},{"drug_id":"busilvex","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nesiritide","indication_name":"Decompensated chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Natrecor","generic_name":"NESIRITIDE","company_name":"Scios Llc","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Natriuretic Peptide","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"xolair","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xolair","company_name":"Taizhou Mabtech Pharmaceutical Co.,Ltd","drug_phase":"marketed","molecular_target":"Ig epsilon chain C region","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"flixotide","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"flixotide","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"flixotide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"imbruvica","indication_name":"Chronic graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imbruvica","company_name":"Rabin Medical Center","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"imbruvica","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imbruvica","company_name":"Rabin Medical Center","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"hydrochlorothiazide","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"hydrochlorothiazide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"hydrochlorothiazide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"sebivo","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sebivo","company_name":"Ziv Hospital","drug_phase":"phase_1","molecular_target":"Capsid protein, Protein P","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"calquence","indication_name":"Chronic lymphocyticleukemia/small lymphocytic lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calquence","company_name":"iOMEDICO AG","drug_phase":"marketed","molecular_target":"Platelet glycoprotein VI, Cytoplasmic tyrosine-protein kinase BMX, Tyrosine-protein kinase Blk","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"erythropoietin","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erythropoietin","company_name":"Nanjing First Hospital, Nanjing Medical University","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":null},{"drug_id":"warfarin","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"prednisone","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"desloratadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clarinex","generic_name":"desloratadine","company_name":"Generic (originally Schering-Plough/MSD)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"Histamine-1 Receptor Antagonist [EPC]","quality_score":54,"revenue":null,"mechanism":"Active metabolite of loratadine with higher potency at H1 receptors and additional anti-inflammatory properties."},{"drug_id":"loratadine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claritin","generic_name":"loratadine","company_name":"Generic (originally Schering-Plough)","drug_phase":"marketed","molecular_target":"Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1","drug_class":"Second-generation antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"spironolactone","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"spironolactone","company_name":"Generic (originally Searle/Pfizer)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"Aldosterone Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Potassium-sparing diuretic and mineralocorticoid receptor antagonist that blocks aldosterone, reducing fluid retention and lowering blood pressure."},{"drug_id":"spironolactone","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"spironolactone","company_name":"Generic (originally Searle/Pfizer)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"Aldosterone Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Potassium-sparing diuretic and mineralocorticoid receptor antagonist that blocks aldosterone, reducing fluid retention and lowering blood pressure."},{"drug_id":"spironolactone","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"spironolactone","company_name":"Generic (originally Searle/Pfizer)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"Aldosterone Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Potassium-sparing diuretic and mineralocorticoid receptor antagonist that blocks aldosterone, reducing fluid retention and lowering blood pressure."},{"drug_id":"gatifloxacin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zymar","generic_name":"GATIFLOXACIN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"gatifloxacin","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zymar","generic_name":"GATIFLOXACIN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"gatifloxacin","indication_name":"Haemophilus Parainfluenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zymar","generic_name":"GATIFLOXACIN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"gatifloxacin","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zymar","generic_name":"GATIFLOXACIN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"gatifloxacin","indication_name":"Staphylococcus Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zymar","generic_name":"GATIFLOXACIN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"gatifloxacin","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zymar","generic_name":"GATIFLOXACIN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"dapa","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"dapa","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"theophyllin","indication_name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"theophyllin","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"theophyllin","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"baraclude","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Baraclude","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Capsid protein, Protein P, Protein P","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"baraclude","indication_name":"Lamivudine-Refractory Chronic Hepatitis B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Baraclude","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Capsid protein, Protein P, Protein P","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"persantin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Persantin","company_name":"Boehringer Ingelheim","drug_phase":"phase_1","molecular_target":"Equilibrative nucleoside transporter 4, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"morphine","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"morphine","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MS Contin","generic_name":"morphine sulfate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","drug_class":"Opioid analgesic","quality_score":10,"revenue":null,"mechanism":"The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids."},{"drug_id":"nandrolone","indication_name":"Anemia of chronic renal failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nandrolon","generic_name":"NANDROLONE","company_name":"","drug_phase":"marketed","molecular_target":"Sex hormone-binding globulin","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxyurea","indication_name":"Resistant chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYUREA","company_name":"","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"carbocysteine","indication_name":"Reduction of sputum viscosity in chronic obstructive pulmonary disease (COPD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mucodyne","generic_name":"carbocysteine","company_name":"","drug_phase":"marketed","molecular_target":"Mucus glycoprotein synthesis","drug_class":"Mucolytic","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"doxercalciferol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hectorol","generic_name":"DOXERCALCIFEROL","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D2 Analog [EPC]","quality_score":70,"revenue":null,"mechanism":"Hectorol works by activating the Vitamin D receptor, which helps regulate calcium levels in the body."},{"drug_id":"ebastine","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bastel","generic_name":"EBASTINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"ebastine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ritonavir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvir","generic_name":"ritonavir","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body."},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chlorambucil","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leukeran","generic_name":"CHLORAMBUCIL","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Cathepsin D","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Leukeran works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"flunisolide","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aerospan Hfa","generic_name":"FLUNISOLIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"flunisolide","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"lactitol","indication_name":"Chronic idiopathic constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pizensy","generic_name":"LACTITOL","company_name":"Braintree Labs","drug_phase":"marketed","molecular_target":"","drug_class":"Osmotic Laxative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"imipenem","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"IMIPENEM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"imipenem","quality_score":70,"revenue":null,"mechanism":"Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ipratropium","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atrovent","generic_name":"IPRATROPIUM","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ipratropium","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atrovent","generic_name":"IPRATROPIUM","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"diflunisal","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dolobid","generic_name":"DIFLUNISAL","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone-hexacetonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aristospan","generic_name":"TRIAMCINOLONE HEXACETONIDE","company_name":"Ethypharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fluocinonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lidex","generic_name":"FLUOCINONIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"carvedilol","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coreg","generic_name":"CARVEDILOL","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"alpha-Adrenergic Blocker [EPC]","quality_score":70,"revenue":null,"mechanism":"Coreg works by blocking the effects of the hormone epinephrine on the heart, reducing its workload and improving its function."},{"drug_id":"asciminib-hydrochloride","indication_name":"Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB HYDROCHLORIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ABL1 kinase of BCR::ABL1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Asciminib binds to the ABL myristoyl pocket, inhibiting ABL1 kinase activity of BCR::ABL1, including mutant forms."},{"drug_id":"fosinopril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monopril","generic_name":"FOSINOPRIL","company_name":"","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":64,"revenue":null,"mechanism":"Monopril works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"calcitriol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcijex","generic_name":"CALCITRIOL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D3 Analog [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"hydromorphone-hydrochloride","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilaudid-Hp","generic_name":"Hydromorphone Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Mu-opioid receptor","drug_class":"Opioid agonist","quality_score":67,"revenue":null,"mechanism":"Full mu-opioid receptor agonist providing analgesia through CNS opioid receptor activation."},{"drug_id":"bumetanide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bumex","generic_name":"BUMETANIDE","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"Loop Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bumetanide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bumex","generic_name":"BUMETANIDE","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"Loop Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"entecavir","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baraclude","generic_name":"ENTECAVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"entecavir","quality_score":70,"revenue":null,"mechanism":"Entecavir works by inhibiting the replication of the hepatitis B virus."},{"drug_id":"entecavir","indication_name":"Lamivudine-Refractory Chronic Hepatitis B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baraclude","generic_name":"ENTECAVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"entecavir","quality_score":70,"revenue":null,"mechanism":"Entecavir works by inhibiting the replication of the hepatitis B virus."},{"drug_id":"halcinonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halog","generic_name":"HALCINONIDE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ceftibuten","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cedax","generic_name":"ceftibuten","company_name":"Burke Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ceftibuten","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cedax","generic_name":"ceftibuten","company_name":"Burke Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ceftibuten","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cedax","generic_name":"ceftibuten","company_name":"Burke Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"epoetin-beta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neorecormon","generic_name":"EPOETIN BETA","company_name":"Roche Registration Limited","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Neorecormon works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production."},{"drug_id":"neurontin","indication_name":"Chronic low back pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."},{"drug_id":"elbasvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepatier","generic_name":"ELBASVIR","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Hepatitis C Virus NS5A Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Zepatier works by blocking the NS5A protein of the hepatitis C virus, preventing it from replicating."},{"drug_id":"lubiprostone","indication_name":"Chronic idiopathic constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amitiza","generic_name":"LUBIPROSTONE","company_name":"Sucampo Pharma Llc","drug_phase":"marketed","molecular_target":"Chloride channel protein 2","drug_class":"Chloride Channel Activator [EPC]","quality_score":65,"revenue":null,"mechanism":"Amitiza works by activating chloride channels in the intestines, increasing fluid secretion and promoting bowel movements."},{"drug_id":"oxitropium","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxytropium Bromide","generic_name":"OXITROPIUM","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"oxitropium","quality_score":null,"revenue":null,"mechanism":"Oxytropium works by blocking the action of acetylcholine, a neurotransmitter that causes airway muscles to contract."},{"drug_id":"morphine-sulfate","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"morphine-sulfate","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duramorph Pf","generic_name":"Morphine Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":80,"revenue":null,"mechanism":"Duramorph Pf works by binding to opioid receptors in the brain and spinal cord, mimicking the natural pain-relieving chemicals in the body."},{"drug_id":"oxymorphone","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"oxymorphone","indication_name":"Chronic pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opana Er","generic_name":"OXYMORPHONE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime-proxetil","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantin","generic_name":"CEFPODOXIME PROXETIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime-proxetil","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantin","generic_name":"CEFPODOXIME PROXETIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"acetazolamide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"imatinib","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"imatinib","indication_name":"Chronic eosinophilic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"imatinib","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"imatinib","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of progression to severe COVID-19, including those who are hospitalized due to COVID-19 or who have mild to moderate COVID-19 with at least one risk factor for progression to severe COVID-19 (e.g., older age, certain chronic medical conditions)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"deferasirox","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exjade","generic_name":"DEFERASIROX","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Flavin reductase (NADPH)","drug_class":"Iron Chelator [EPC]","quality_score":10,"revenue":null,"mechanism":"Exjade works by binding to iron in the body and removing it through the urine."},{"drug_id":"doxepin","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"prednicarbate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dermatop","generic_name":"PREDNICARBATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cilastatin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"CILASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dipeptidase 1","drug_class":"Renal Dehydropeptidase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body."},{"drug_id":"tegaserod","indication_name":"Chronic idiopathic constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zelnorm","generic_name":"TEGASEROD","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"Serotonin-4 Receptor Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fostamatinib","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavalisse","generic_name":"FOSTAMATINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets."},{"drug_id":"daclatasvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daklinza","generic_name":"DACLATASVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Hepatitis C Virus NS5A Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"plecanatide","indication_name":"Chronic idiopathic constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trulance","generic_name":"PLECANATIDE","company_name":"Salix","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"Guanylate Cyclase-C Agonist [EPC]","quality_score":65,"revenue":null,"mechanism":"Trulance works by stimulating the guanylate cyclase-C receptor to increase fluid secretion in the intestines."},{"drug_id":"nitroprusside","indication_name":"Acute exacerbation of chronic congestive heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sodium Nitroprusside","generic_name":"NITROPRUSSIDE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Vasodilator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ruxience","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"bulevirtide","indication_name":"Chronic infection caused by Hepatitis D virus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hepcludex","generic_name":"BULEVIRTIDE","company_name":"MYR GmbH","drug_phase":"marketed","molecular_target":"Sodium/bile acid cotransporter","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"bulevirtide","indication_name":"Chronic viral hepatitis B with hepatitis D","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hepcludex","generic_name":"BULEVIRTIDE","company_name":"MYR GmbH","drug_phase":"marketed","molecular_target":"Sodium/bile acid cotransporter","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"alemtuzumab","indication_name":"Recurrent chronic lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Campath","generic_name":"ALEMTUZUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"CD52-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction."},{"drug_id":"alemtuzumab","indication_name":"Refractory chronic lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Campath","generic_name":"ALEMTUZUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"CAMPATH-1 antigen","drug_class":"CD52-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction."},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic heart disease, including congestive heart failure, coronary artery disease, or cardiac transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic lung disease, including chronic obstructive pulmonary disease (COPD) and asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"incobotulinumtoxina","indication_name":"Chronic sialorrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"diprophylline","indication_name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diphyllin","generic_name":"diprophylline","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","drug_class":"diprophylline","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"diprophylline","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diphyllin","generic_name":"diprophylline","company_name":"","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","drug_class":"diprophylline","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"mometasone-furoate","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"mometasone-furoate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe chronic spontaneous urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe lichen simplex chronicus in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe chronic spontaneous urticaria in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or alcoholism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Acute bacterial exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime","indication_name":"Haemophilus Parainfluenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"diflorasone-diacetate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Psorcon","generic_name":"DIFLORASONE DIACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"paromomycin","indication_name":"Chronic intestinal amebiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ameparomo","generic_name":"PAROMOMYCIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Antiprotozoal","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"probenecid","indication_name":"Chronic gouty arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Col-Probenecid","generic_name":"probenecid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 9","drug_class":"probenecid","quality_score":10,"revenue":null,"mechanism":"ORLYNVAH combines sulopenem etzadroxil, a penem antibacterial, with probenecid to increase sulopenem's plasma concentration by inhibiting its renal clearance."},{"drug_id":"glecaprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mavyret","generic_name":"GLECAPREVIR","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"","drug_class":"Hepatitis C Virus NS5A Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Mavyret works by blocking the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating."},{"drug_id":"sotagliflozin","indication_name":"Chronic kidney disease at increased risk of cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"alglucerase","indication_name":"Chronic non-neuropathic Gaucher's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceredase","generic_name":"ALGLUCERASE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"cefditoren-pivoxil","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefditoren Pivoxyl","generic_name":"CEFDITOREN PIVOXIL","company_name":"Vansen Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"cefditoren-pivoxil","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefditoren Pivoxyl","generic_name":"CEFDITOREN PIVOXIL","company_name":"Vansen Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"cefditoren-pivoxil","indication_name":"Haemophilus Parainfluenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefditoren Pivoxyl","generic_name":"CEFDITOREN PIVOXIL","company_name":"Vansen Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"cefditoren-pivoxil","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefditoren Pivoxyl","generic_name":"CEFDITOREN PIVOXIL","company_name":"Vansen Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"cefditoren-pivoxil","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefditoren Pivoxyl","generic_name":"CEFDITOREN PIVOXIL","company_name":"Vansen Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"anakinra","indication_name":"Chronic infantile neurological, cutaneous and articular syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kineret","generic_name":"ANAKINRA","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Kineret blocks the action of interleukin-1, a protein that promotes inflammation."},{"drug_id":"norfloxacin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Chronic Bacterial Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Chronic Enterococcus faecalis Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Chronic Escherichia coli Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Chronic Staphylococcus epidermidis Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Chronic tubotympanic suppurative otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Haemophilus Parainfluenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Klebsiella Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Staphylococcus Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Chronic Bacterial Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Chronic Enterococcus faecalis Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Chronic Escherichia coli Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Chronic Staphylococcus epidermidis Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Chronic tubotympanic suppurative otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"amcinonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclocort","generic_name":"AMCINONIDE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"busulfan","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"asunaprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunvepra","generic_name":"ASUNAPREVIR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"dipyridamole","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Persantine","generic_name":"DIPYRIDAMOLE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 1","drug_class":"Platelet Aggregation Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Persantine works by inhibiting platelet activation and aggregation by blocking the equilibrative nucleoside transporter 1."},{"drug_id":"terbutaline","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brethine","generic_name":"TERBUTALINE","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"terbutaline","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metolazone","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zaroxolyn","generic_name":"METOLAZONE","company_name":"I3 Pharms","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 7","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metolazone","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zaroxolyn","generic_name":"METOLAZONE","company_name":"I3 Pharms","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 7","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"velaglucerase-alfa","indication_name":"Chronic non-neuropathic Gaucher's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vpriv","generic_name":"VELAGLUCERASE ALFA","company_name":"Shire Human Genetic","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"VELAGLUCERASE ALFA replaces the deficient enzyme glucocerebrosidase in patients with Gaucher's disease."},{"drug_id":"betamethasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"ciprofloxacin","indication_name":"Chronic Bacterial Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"clarithromycin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biaxin","generic_name":"clarithromycin","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Clarithromycin is a macrolide antimicrobial drug."},{"drug_id":"furosemide","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lasix","generic_name":"furosemide","company_name":"Generic (originally Hoechst AG)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"Loop Diuretic [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"furosemide","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lasix","generic_name":"furosemide","company_name":"Generic (originally Hoechst AG)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"Loop Diuretic [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"digoxin","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lanoxin","generic_name":"digoxin","company_name":"Generic (originally Burroughs Wellcome/GSK)","drug_phase":"marketed","molecular_target":"Nuclear receptor ROR-gamma, Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2","drug_class":"Cardiac Glycoside [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"haloperidol-decanoate","indication_name":"Chronic schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Haldol","generic_name":"HALOPERIDOL DECANOATE","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Typical Antipsychotic","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"riociguat","indication_name":"Chronic thromboembolic pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adempas","generic_name":"RIOCIGUAT","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1","drug_class":"Soluble Guanylate Cyclase Stimulator [EPC]","quality_score":10,"revenue":null,"mechanism":"Adempas works by stimulating the soluble guanylate cyclase enzyme to increase levels of cyclic guanosine monophosphate (cGMP), a signaling molecule that helps to relax blood vessels."},{"drug_id":"cefixime","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suprax","generic_name":"CEFIXIME","company_name":"","drug_phase":"marketed","molecular_target":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1","drug_class":"cefixime","quality_score":10,"revenue":null,"mechanism":"Suprax works by inhibiting the bacterial enzyme 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1, disrupting bacterial cell wall synthesis."},{"drug_id":"cefixime","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suprax","generic_name":"CEFIXIME","company_name":"","drug_phase":"marketed","molecular_target":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1","drug_class":"cefixime","quality_score":10,"revenue":null,"mechanism":"Suprax works by inhibiting the bacterial enzyme 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1, disrupting bacterial cell wall synthesis."},{"drug_id":"cefixime","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suprax","generic_name":"CEFIXIME","company_name":"","drug_phase":"marketed","molecular_target":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1","drug_class":"cefixime","quality_score":10,"revenue":null,"mechanism":"Suprax works by inhibiting the bacterial enzyme 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1, disrupting bacterial cell wall synthesis."},{"drug_id":"ramipril","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Altace","generic_name":"RAMIPRIL","company_name":"King Pfizer","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure."},{"drug_id":"chembl-chembl1200796","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"chembl-chembl1200796","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"dicloxacillin","indication_name":"Continuation Therapy for Chronic Osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pathocil","generic_name":"DICLOXACILLIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Penicillin-class Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"dasabuvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viekira Pak (Copackaged)","generic_name":"DASABUVIR","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Protein cereblon","drug_class":"Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"duvelisib","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Copiktra","generic_name":"DUVELISIB","company_name":"Secura","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Copiktra works by blocking an enzyme that helps cancer cells grow and multiply."},{"drug_id":"ethacrynic-acid","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ethacrynic-acid","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Edecrin","generic_name":"ETHACRYNIC ACID","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glutathione S-transferase P","drug_class":"Loop Diuretic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"levofloxacin","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"levofloxacin","indication_name":"Chronic Enterococcus faecalis Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"levofloxacin","indication_name":"Chronic Escherichia coli Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"levofloxacin","indication_name":"Chronic Staphylococcus epidermidis Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"umec","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"UMEC","company_name":"Glaxo Grp England","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":"UmeC is a small molecule drug that works by interacting with a specific target in the body."},{"drug_id":"umec","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"UMEC","company_name":"Glaxo Grp England","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":"UmeC is a small molecule drug that works by interacting with a specific target in the body."},{"drug_id":"oxacillin","indication_name":"Continuation Therapy for Chronic Osteomyelitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bactocill In Plastic Container","generic_name":"OXACILLIN","company_name":"Apothecon","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"oxycontin","indication_name":"Chronic Pain with Opioid Tolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OXYCONTIN®","company_name":"Mundipharma (China) Pharmaceutical Co. Ltd","drug_phase":"marketed","molecular_target":"Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"OxyContin is a medication that works by binding to opioid receptors in the brain, altering the way the body perceives pain."},{"drug_id":"cefditoren","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFDITOREN","company_name":"","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein, Penicillin-binding protein 3","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefditoren","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFDITOREN","company_name":"","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein, Penicillin-binding protein 3","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefditoren","indication_name":"Haemophilus Parainfluenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFDITOREN","company_name":"","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein, Penicillin-binding protein 3","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefditoren","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFDITOREN","company_name":"","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein, Penicillin-binding protein 3","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefditoren","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFDITOREN","company_name":"","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein, Penicillin-binding protein 3","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"forxiga","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"forxiga","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fludarabin","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludarabin","company_name":"Azienda Ospedaliera San Giovanni Battista","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Chronic ulcerative proctitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zemplar","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zemplar","company_name":"Danderyd Hospital","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"incruse","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Incruse","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"incruse","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Incruse","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"serevent","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Serevent","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bendamustin","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bendamustin","company_name":"Meir Medical Center","drug_phase":"marketed","molecular_target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"norvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Norvir","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxycarbamide","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamide","company_name":"University of Birmingham","drug_phase":"phase_3","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"siklos","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Siklos","company_name":"Theravia","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"jardiance","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Jardiance","company_name":"University of Louisville","drug_phase":"marketed","molecular_target":"Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"brovana","indication_name":"Chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brovana","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-3 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"brovana","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brovana","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-3 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"daxas","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daxas","company_name":"AstraZeneca","drug_phase":"phase_2","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"daxas","indication_name":"Severe chronic obstructive pulmonary disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daxas","company_name":"AstraZeneca","drug_phase":"phase_2","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fludara","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludara","company_name":"Celyad Oncology SA","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gazyvaro","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gazyvaro","company_name":"Incyte Corporation","drug_phase":"phase_1","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"arzerra","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arzerra","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mircera","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mircera","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Chronic Bacterial Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Chronic Enterococcus faecalis Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Chronic Escherichia coli Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Chronic Staphylococcus epidermidis Prostatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Chronic tubotympanic suppurative otitis media","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Moraxella Catarrhalis Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulfex","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulphan","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"sialanar","indication_name":"Chronic obstructive lung disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sialanar","company_name":"Proveca Pharma Limited","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ribavarin","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ribavarin","company_name":"Charles University, Czech Republic","drug_phase":"discontinued","molecular_target":"Cytosolic purine 5'-nucleotidase, Adenosine kinase, Ectonucleotide pyrophosphatase/phosphodiesterase family member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"rocaltrol","indication_name":"Hyperparathyroidism Secondary to Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rocaltrol","company_name":"Shandong University","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Acute exacerbation of chronic bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Haemophilus Influenzae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Streptococcus Pneumoniae Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mavik","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mavik","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"Asthma-chronic obstructive pulmonary disease overlap syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"Chronic Obstructive Pulmonary Disease with Bronchospasms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"spirolactone","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"spirolactone","company_name":"Second Xiangya Hospital of Central South University","drug_phase":"phase_1","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"spirolactone","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"spirolactone","company_name":"Second Xiangya Hospital of Central South University","drug_phase":"phase_1","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"spirolactone","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"spirolactone","company_name":"Second Xiangya Hospital of Central South University","drug_phase":"phase_1","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tasigna","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasigna","company_name":"XSpray Microparticles","drug_phase":"marketed","molecular_target":"Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tasigna","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasigna","company_name":"XSpray Microparticles","drug_phase":"marketed","molecular_target":"Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tasigna","indication_name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasigna","company_name":"XSpray Microparticles","drug_phase":"marketed","molecular_target":"Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zydelig","indication_name":"Chronic lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zydelig","company_name":"University of Maryland, Baltimore","drug_phase":"marketed","molecular_target":"DNA-dependent protein kinase catalytic subunit, Phosphatidylinositol 3-kinase catalytic subunit type 3, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"neorecormon","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neorecormon","company_name":"Centre Hospitalier Universitaire, Amiens","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nplate","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nplate","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"desloratadin","indication_name":"Chronic idiopathic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Desloratadin","company_name":"Max Zeller Soehne AG","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"desferrioxamine","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"desferrioxamine","company_name":"Brigham and Women's Hospital","drug_phase":"phase_3","molecular_target":"Deoxyhypusine hydroxylase, Hypoxia-inducible factor 1-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hepsera","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hepsera","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"DNA polymerase subunit gamma-1, Capsid protein, Protein P","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xromi","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xromi","company_name":"Nova Laboratories Limited","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamid","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamid","company_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","drug_phase":"phase_2","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"omacetaxine","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omacetaxine","company_name":"University of Illinois at Chicago","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mometasone","indication_name":"Chronic Non-Allergic Rhinitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"mometasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"peginterferon-alfa-2a","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pegasys","generic_name":"PEGINTERFERON ALFA-2A","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"peginterferon-alfa-2a","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pegasys","generic_name":"PEGINTERFERON ALFA-2A","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naftidrofuryl-oxalate","indication_name":"Chronic Occlusive Peripheral Arterial Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Praxilene","generic_name":"naftidrofuryl oxalate","company_name":"Merck Serono (originally Lipha)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"5-HT2 receptor antagonist, Peripheral vasodilator","quality_score":31,"revenue":null,"mechanism":"A 5-HT2 receptor antagonist that improves peripheral blood flow and cellular metabolism by blocking serotonin-mediated vasoconstriction and enhancing aerobic metabolism in ischaemic tissues."},{"drug_id":"imatinib","indication_name":"Chronic Myelocytic Leukemia Accelerated Phase","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"zanubrutinib","indication_name":"Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brukinsa","generic_name":"ZANUBRUTINIB","company_name":"BeiGene","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"verapamil-hydrochloride","indication_name":"Chronic stable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"chlorothiazide","indication_name":"Edema in Chronic Renal Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nicardipine-hydrochloride","indication_name":"Chronic stable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NICARDIPINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Calcium ion channels","drug_class":"Calcium channel blocker","quality_score":53,"revenue":null,"mechanism":"Nicardipine blocks calcium ion influx into vascular smooth muscle, causing relaxation with minimal effect on cardiac muscle."},{"drug_id":"glycopyrronium-bromide","indication_name":"Reduce chronic severe drooling","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cuvposa","generic_name":"GLYCOPYRRONIUM BROMIDE","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":62,"revenue":null,"mechanism":"Cuvposa works by blocking the action of a chemical called acetylcholine, which stimulates the muscarinic receptors in the body."},{"drug_id":"azacitidine","indication_name":"Chronic Myelomonocytic Leukemia (CMMoL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"metirosine","indication_name":"Chronic treatment of malignant pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demser","generic_name":"metirosine","company_name":"Aton Pharma Vpna","drug_phase":"marketed","molecular_target":"Tyrosine 3-monooxygenase","drug_class":"Catecholamine Synthesis Inhibitor [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"filgrastim-txid","indication_name":"Severe Chronic Neutropenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NYPOZI","generic_name":"FILGRASTIM-TXID","company_name":"TANVEX BIOPHARMA USA INC","drug_phase":"marketed","molecular_target":"Specific cell surface receptors on hematopoietic cells","drug_class":"Leukocyte Growth Factor [EPC]","quality_score":50,"revenue":null,"mechanism":"G-CSF binds to specific receptors on hematopoietic cells, stimulating neutrophil production and function."},{"drug_id":"fostamatinib","indication_name":"Thrombocytopenia in Chronic ITP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavalisse","generic_name":"FOSTAMATINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets."},{"drug_id":"incobotulinumtoxina","indication_name":"Chronic sialorrhea","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"acetazolamide","indication_name":"Chronic simple (open-angle) glaucoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"hydroxychloroquine","indication_name":"Chronic discoid lupus erythematosus treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"loteprednol-etabonate-and-tobramycin","indication_name":"Chronic anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"loteprednol etabonate and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial [EPC]","quality_score":31,"revenue":null,"mechanism":null},{"drug_id":"macitentan-and-tadalafil","indication_name":"Chronic treatment of PAH","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Macitentan and Tadalafil","company_name":"Humanis Saglık Anonim Sirketi","drug_phase":"marketed","molecular_target":"","drug_class":"Phosphodiesterase 5 Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1201576","indication_name":"Previously Untreated Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RITUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1201576","indication_name":"Previously Treated Chronic Lymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RITUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"tenofovir-disoproxil-fumarate","indication_name":"Chronic Hepatitis B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TENOFOVIR DISOPROXIL FUMARATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":34,"revenue":null,"mechanism":null},{"drug_id":"calcitriol-capsules","indication_name":"Hypocalcemia in Chronic Renal Dialysis Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calcitriol capsules","company_name":"Indonesia University","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin D3 Analog [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"ziconotide-acetate","indication_name":"Severe Chronic Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ZICONOTIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":32,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103744","indication_name":"Chronic Pain Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MORPHINE SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"tezepelumab","indication_name":"Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tezspire","generic_name":"TEZEPELUMAB","company_name":"AstraZeneca / Amgen","drug_phase":"marketed","molecular_target":"","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1489","indication_name":"Chronic Myelomonocytic Leukemia (CMMoL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZACITIDINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"prucalopride","indication_name":"Chronic Idiopathic Constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PRUCALOPRIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"colistimethate","indication_name":"Acute or Chronic Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"COLISTIMETHATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"potassium-bicarbonate","indication_name":"Chronic Digitalis Intoxication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"POTASSIUM BICARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"metyrosine","indication_name":"Chronic treatment of malignant pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"METYROSINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Catecholamine Synthesis Inhibitor [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"febuxostat-tablets","indication_name":"Chronic management of hyperuricemia in gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Febuxostat Tablets","company_name":"Mostafa Bahaa","drug_phase":"marketed","molecular_target":"","drug_class":"Xanthine Oxidase Inhibitor [EPC]","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"furosemide-injection","indication_name":"Edema in adults with chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Furosemide Injection","company_name":"Johannes Grand","drug_phase":"marketed","molecular_target":"","drug_class":"Loop Diuretic [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"furosemide-injection","indication_name":"Edema in adults with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Furosemide Injection","company_name":"Johannes Grand","drug_phase":"marketed","molecular_target":"","drug_class":"Loop Diuretic [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"ferulic-acid","indication_name":"Chronic weight management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ferulic Acid","company_name":"Salah Awad Alanazi","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Chemical Allergen [EPC]","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"caduet","indication_name":"Chronic Stable Angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"flumetasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flucorticin","generic_name":"flumetasone","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"flumetasone","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"epoetin-theta","indication_name":"Anemia of chronic renal failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eporatio","generic_name":"EPOETIN THETA","company_name":"","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"diovan","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Diovan","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Platelet glycoprotein VI, Type-1 angiotensin II receptor, Angiotensin II receptor (AT-1) type-1","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"aclatonium","indication_name":"Chronic gastritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abovis","generic_name":"ACLATONIUM","company_name":"","drug_phase":"phase_2","molecular_target":"Muscarinic acetylcholine receptor","drug_class":"aclatonium","quality_score":23,"revenue":null,"mechanism":"Abovis works by binding to the muscarinic acetylcholine receptor, a protein that plays a key role in regulating various bodily functions."},{"drug_id":"sovaldi","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sovaldi","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Cereblon isoform 4, Genome polyprotein, NS5","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"spironolacton","indication_name":"Chronic heart failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Spironolacton","company_name":"ACS Biomarker","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"spironolacton","indication_name":"Peripheral Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Spironolacton","company_name":"ACS Biomarker","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"spironolacton","indication_name":"Pulmonary Edema due to Chronic Heart Failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Spironolacton","company_name":"ACS Biomarker","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"dabigatran-etexilate-de","indication_name":"Prevention of Thromboembolism with Chronic Atrial Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"},{"drug_id":"alclometasone-dipropionate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclovate","generic_name":"ALCLOMETASONE DIPROPIONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic lymphocytic leukemia (CLL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (genotype 1)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (treatment-naïve and treatment-experienced)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (Japanese population)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odv-25-mg","indication_name":"Chronic Hepatitis C (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODV 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"oleum-neutralicum","indication_name":"Chronic lymphoid leukemia with vitamin D3 substitution","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"oleum neutralicum","company_name":"Semmelweis University","drug_phase":"discontinued","molecular_target":"Unknown; possibly vitamin D receptor (VDR) if vitamin D3-based","drug_class":"Unknown; possibly vitamin D analog or immunomodulator","quality_score":null,"revenue":null,"mechanism":"Mechanism of action unknown; product appears to be a vitamin D3 formulation studied in hematologic malignancies."},{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of chronic rhinosinusitis with and without nasal polyps","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."},{"drug_id":"scopolamine","indication_name":"Chronic obstructive pulmonary disease (COPD)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SCOPOLAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptors","drug_class":"Anticholinergic [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"dextroamphetamine","indication_name":"Chronic Fatigue Syndrome","indication_type":"pipeline","phase":"Phase 4","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXTROAMPHETAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Dopamine transporter (DAT), Norepinephrine transporter (NET)","drug_class":"Central nervous system stimulant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cephalexin","indication_name":"Chronic urinary tract infection","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."}],"offLabel":[],"totalMarketed":815,"totalPipeline":10},"trials":{"data":[{"nct_id":"NCT03279822","title":"Association Analysis for Chronic Diseases Based on Resident Health Records by Using Big Data Methods","phase":"","overall_status":"COMPLETED","enrollment_count":10000000,"lead_sponsor_name":"Shanghai Tongji Hospital, Tongji University School of Medicine","has_results":false},{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT04053335","title":"Smarter Care Virginia, Examining Low-Value Care in Virginia","phase":"","overall_status":"COMPLETED","enrollment_count":5000000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06239129","title":"The Stockholm CREAtinine Measurements Project","phase":"","overall_status":"COMPLETED","enrollment_count":3200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06053541","title":"Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change","phase":"","overall_status":"COMPLETED","enrollment_count":3015000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05932901","title":"OPTIMISE-CKD Drug Utilization","phase":"","overall_status":"COMPLETED","enrollment_count":2682052,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04206098","title":"Chart Review of Patients With COPD, Using Electronic Medical Records and Artificial Intelligence","phase":"","overall_status":"UNKNOWN","enrollment_count":2500000,"lead_sponsor_name":"Sociedad Española de Neumología y Cirugía Torácica","has_results":false},{"nct_id":"NCT03084172","title":"Systemic Redesign and Demonstration for Early Detection, Evaluation and Management of Chronic Kidney Disease in Shanghai","phase":"","overall_status":"UNKNOWN","enrollment_count":2000000,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT04926233","title":"Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study","phase":"","overall_status":"COMPLETED","enrollment_count":1371146,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04847531","title":"REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease","phase":"","overall_status":"COMPLETED","enrollment_count":1006361,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05914259","title":"An Observational Study to Learn More How Chronic Kidney Disease Gradually Changes Over Time in Adults Using Electronic Healthcare Records (CKD Natural History Study)","phase":"","overall_status":"COMPLETED","enrollment_count":969394,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05813652","title":"Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1","phase":"","overall_status":"COMPLETED","enrollment_count":919928,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT05953701","title":"Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics","phase":"","overall_status":"COMPLETED","enrollment_count":800211,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05480176","title":"The China National COPD Screening Program","phase":"","overall_status":"UNKNOWN","enrollment_count":800000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05520931","title":"Pain-related Long Covid in Covid-19 Survivors","phase":"","overall_status":"UNKNOWN","enrollment_count":600000,"lead_sponsor_name":"Aalborg University","has_results":false},{"nct_id":"NCT04417725","title":"Burden of Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), and Comorbid T2DM/CKD in Alberta, Canada","phase":"","overall_status":"COMPLETED","enrollment_count":588170,"lead_sponsor_name":"Medlior Health Outcomes Research Ltd","has_results":false},{"nct_id":"NCT04750915","title":"NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":566398,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05443503","title":"Stanford Spine Keeper - Managing Your Low Back Pain","phase":"NA","overall_status":"SUSPENDED","enrollment_count":500000,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT05744713","title":"An Observational Study of Patients With Chronic Liver Disease","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500000,"lead_sponsor_name":"Target PharmaSolutions, Inc.","has_results":false},{"nct_id":"NCT05004428","title":"A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)","phase":"","overall_status":"COMPLETED","enrollment_count":336376,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06330480","title":"Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":320000,"lead_sponsor_name":"Prof. Dr. Folkert W. Asselbergs","has_results":false},{"nct_id":"NCT04350866","title":"Enhancing Access to Insomnia (EASI) Care in VA PCMHI Clinics","phase":"","overall_status":"COMPLETED","enrollment_count":277920,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT05848206","title":"Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.","phase":"","overall_status":"COMPLETED","enrollment_count":251831,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06622304","title":"Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels","phase":"","overall_status":"COMPLETED","enrollment_count":250736,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT05248412","title":"The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":250000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT07416266","title":"Lower Respiratory Tract Infections Managed in Primary Care in France","phase":"","overall_status":"COMPLETED","enrollment_count":230066,"lead_sponsor_name":"Hôpital Raymond Poincaré","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT03958760","title":"Characteristics, Treatment, and Economic Burden of Patients With CVD,CKD or at High Cardiovascular Risk","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT07093684","title":"Dementia and Kidney Disease: Epidemiological Approaches to Risk Factors and Treatment Strategies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03108794","title":"A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B","phase":"","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT02612688","title":"Pragmatic Trial of Video Education in Nursing Homes","phase":"NA","overall_status":"COMPLETED","enrollment_count":197692,"lead_sponsor_name":"Brown University","has_results":true},{"nct_id":"NCT04541498","title":"Impact of Air Pollution and Climate Changes on the Epidemiology of Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":150000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT06608212","title":"An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06102187","title":"Cohort Study in Fujian Province","phase":"","overall_status":"RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Fujian Provincial Hospital","has_results":false},{"nct_id":"NCT03200379","title":"Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan","phase":"","overall_status":"RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","has_results":false},{"nct_id":"NCT06370468","title":"The Epidemiological and Intrinsic Characteristics of Chronic Rhinitis","phase":"","overall_status":"RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Zheng Liu ENT","has_results":false},{"nct_id":"NCT05457868","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists","phase":"","overall_status":"COMPLETED","enrollment_count":124117,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06769646","title":"SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data","phase":"","overall_status":"COMPLETED","enrollment_count":110074,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03288805","title":"Cohort Study in South China","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110000,"lead_sponsor_name":"Min Xia","has_results":false},{"nct_id":"NCT02917317","title":"South China Prospective Cohort Study of Chronic Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":110000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05741112","title":"The Long COVID-19 Wearable Device Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":100500,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":false},{"nct_id":"NCT04302974","title":"Cohort Study on Patient Outcomes, Effectiveness and Cost-effectiveness of Intervention Programmes for DM/HT Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT03357302","title":"Risk Factors Associated With the Global Burden of Disease in Reunion Island and Comparison With Mainland France and Indian Ocean Countries","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"Centre Hospitalier Universitaire de la Réunion","has_results":false},{"nct_id":"NCT05315895","title":"The Dampness Syndrome of Chinese Medicine Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Guangzhou University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT06596213","title":"Hepatitis Inequalities Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07128966","title":"Direct to Patient Minimal Risk Biospecimen and Data Collection Research","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Joined Bio","has_results":false},{"nct_id":"NCT06512493","title":"South East (Zuid Oost) Netherlands Heart Registry","phase":"","overall_status":"RECRUITING","enrollment_count":99999,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT05179512","title":"Replication of the INSPIRE Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":98278,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05188885","title":"A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":90000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}